öλÔÓéÀֵǼÈë¿ÚÏÂÔØ

µ¼Ê¦ÐÕÃû£ºÍòÏ×Ò¢
ÐÔ±ð£º
ÈËÆøÖ¸Êý£º114

ËùÊôԺУ£º´óÁ¬Ò½¿Æ´óѧ
ËùÊôԺϵ£ºµÚÒ»ÁÙ´²Ñ§Ôº
Ö°³Æ£º½ÌÊÚ
µ¼Ê¦ÀàÐÍ£º²©µ¼
ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÖØ֢ҽѧ¡¢ÄÚ¿ÆѧÖØ֢ҽѧ
Ñо¿ÁìÓò£º ŧ¶¾Ö¢ºÍ¸ÐȾÐÔÐÝ¿Ë¡¢ÑÏÖØ´´É˼°´´ÉËÐÔÐÝ¿Ë¡¢¼±ÐÔ·Î˨Èû¡¢¼±ÐÔºôÎü¾½ÆÈ×ÛºÏÕ÷¡¢¶àÆ÷¹Ù¹¦ÄÜÕÏ°­×Û... [Õ¹¿ª]


Ñо¿ÁìÓò£º ŧ¶¾Ö¢ºÍ¸ÐȾÐÔÐÝ¿Ë¡¢ÑÏÖØ´´É˼°´´ÉËÐÔÐÝ¿Ë¡¢¼±ÐÔ·Î˨Èû¡¢¼±ÐÔºôÎü¾½ÆÈ×ÛºÏÕ÷¡¢¶àÆ÷¹Ù¹¦ÄÜÕÏ°­×ÛºÏÕ÷¡¢ÖضÈÓªÑø²»Á¼µÈ¡£ [ÊÕÆð]




¸öÈ˼òÊö :
´óÁ¬Ò½¿Æ´óѧÖØ֢ҽѧÑо¿ËùËù³¤ºÍÖØ֢ҽѧ½ÌÑÐÊÒÖ÷ÈΡ¢¸½ÊôÒ»ÔºÖØ֢ҽѧ¿Æ£¨ÎÀÉú²¿È«¹úÁÙ´²Öصãר¿Æ¡¢´óÁ¬ÊÐÖØ֢ҽѧÖÐÐÄ£©Ö÷ÈΣ¬½ÌÊÚ£¬Ö÷ÈÎҽʦ£¬²©Ê¿Ñо¿Éúµ¼Ê¦£¬Öй²²úµ³Ô±£¬1990Äê6Ô±ÏÒµÓÚ´óÁ¬Ò½Ñ§Ôº£¬»ñºôÎüÄÚ¿Æ˶ʿѧλ¡£ÖйúҽʦЭ»áÖØ֢ҽѧҽʦ·Ö»á¸±»á³¤¡¢ÖлªÒ½Ñ§»áÖØ֢ҽѧ·Ö»áίԱ¡¢ÖлªÒ½Ñ§»á´´ÉËѧ·Ö»á´´ÉËÓë¸ÐȾίԱ¡¢Öйú²¡ÀíÉúÀíѧ»áÀíÊ¡¢Öйú²¡ÀíÉúÀíѧ»áΣÖز¡Ò½Ñ§öλÔÓéÀֵǼÈë¿ÚÏÂÔØίԱ»á³£Î¯¡¢Îâ½×ƽҽѧ»ù½ð»áÂé×íÖØ֢ҽѧ²¿Î¯Ô±¡¢ÖйúҽʦЭ»á¼±¾È¸´ËÕöλÔÓéÀֵǼÈë¿ÚÏÂÔØίԱ»áίԱ¡¢ÁÉÄþʡҽѧ»áÖØ֢ҽѧ·Ö»áºòÈÎÖ÷ί¡¢´óÁ¬ÊÐҽѧ»áÀíÊ¡¢´óÁ¬ÊÐҽѧ»áÖØ֢ҽѧ·Ö»áÖ÷ί¡¢´óÁ¬ÊÐҽʦЭ»áÀíÊ¡¢´óÁ¬ÊÐҽʦЭ»áÖØ֢ҽѧҽʦ·Ö»áÖ÷ί¡¢ÎÀÉú²¿ÖØ֢ҽѧÖÊ¿ØÆÀ¼ÛÖÐÐÄר¼ÒίԱ»áίԱ¡¢ÁÉÄþÊ¡ICUÖÊ¿ØÖÐÐĸ±Ö÷ÈΡ¢´óÁ¬ÊÐÖØ֢ҽѧ£¨ICU£©ÖÊ¿ØÖÐÐÄÖ÷ÈΣ»µ£Èζà¼ÒҽѧÔÓÖ¾µÄ±àί¡£Ö÷Òª´ÓÊÂÖØ֢ҽѧµÄÒ½ÁÆ¡¢½ÌѧºÍ¿ÆÑй¤×÷£¬¶Ôŧ¶¾Ö¢ºÍ¸ÐȾÐÔÐÝ¿Ë¡¢ÑÏÖØ´´É˼°´´ÉËÐÔÐÝ¿Ë¡¢¼±ÐÔ·Î˨Èû¡¢¼±ÐÔºôÎü¾½ÆÈ×ÛºÏÕ÷¡¢¶àÆ÷¹Ù¹¦ÄÜÕÏ°­×ÛºÏÕ÷¡¢ÖضÈÓªÑø²»Á¼µÈΣÖØÖ¢ÓнÏÉîµÄÔìÒè¡£ÒÑÍê³ÉÊ¡Êм¶¿ÎÌâ9ÏĿǰÕýÔÚÑо¿µÄÊ¡²¿¼¶¿ÎÌâ3Ïî¡£ÒÑÔÚ¹úÄÚÍâҽѧÔÓÖ¾ÉÏ·¢±íÂÛÖø50Óàƪ£¬×ÛÊö25ƪ£¬ÒëÎÄ185ƪ¡£ÒÑÖ÷±à»ò²Î±àרÖøºÍ½Ì²Ä25²¿£¬»ñÁÉÄþÊ¡Õþ¸®¿Æ¼¼½ø²½ÈýµÈ½±1ÏʡÊм¶ÓÅÐãѧÊõÂÛÎÄ5ƪ£¬ÁÉÄþÊ¡×ÔÈ»¿ÆѧѧÊõ³É¹û½±ÈýµÈ½±1Ï´óÁ¬ÊпƼ¼½ø²½ÈýµÈ½±1Ï´óÁ¬Ò½¿Æ´óѧ¸½ÊôÒ»ÔºÁÙ´²Ð¼¼ÊõÓ¦ÓöþµÈ½±1ÏʵÓÃÐÂÐÍרÀû1Ïî¡£¶à´Î»ñÔº¼¶ÏȽø¹¤×÷Õß¡¢ÁÙ´²ÓÅÐã´ø½ÌÀÏʦ¡£±»Æ¸ÎªÁÉÄþÊ¡ÎÀÉúϵÁУ¨Î÷Ò½£©¸ß¼¶öλÔÓéÀֵǼÈë¿ÚÏÂÔؼ¼Êõ×ʸñÆÀÉóίԱ»áÖØ֢ҽѧ¼°ºôÎüÄÚ¿ÆÆÀÉóר¼Ò£¬ÖлªÒ½Ñ§»á¡¢ÁÉÄþʡҽѧ»á¼°´óÁ¬ÊÐҽѧ»áÒ½ÁÆʹʼ¼Êõ¼ø¶¨Î¯Ô±»áר¼Ò£¬ÎÀÉú²¿¡¢ÁÉÄþÊ¡¼°´óÁ¬ÊÐÍ»·¢¹«¹²ÎÀÉúʼþר¼Ò×ÉѯίԱ»áίԱ¡£

¿ÆÑй¤×÷ :
ÔÚÑÐÏîÄ¿[1]¹ú¼ÒÁÙ´²Öصãר¿Æ-ÖØ֢ҽѧ£¬Ô­ÎÀÉú²¿£¬2012-11-11~2017-11-11£¬500Íò£¬µÚ1Ãû
[2]ÖлªÒ½Ñ§»áÁÙ´²Ò½Ñ§¿ÆÑÐרÏî×ʽð£¨ICUÀÏÄêÚÞÍýʶ±ðÆÀ¹À¼°ÓÒÃÀÍÐß䶨Ԥ·À×÷ÓõÄÇ°Õ°ÐÔÑо¿£©£¬ÖлªÒ½Ñ§»á£¬2014-1-15~2017-3-31£¬9Íò£¬µÚ1Ãû
[3]´óÁ¬ÊÐÌá¸ßÒ½ÁÆÈíʵÁ¦ÏîÄ¿£¨´óÁ¬ÊÐÖØ֢ҽѧÖÐÐÄ£©£¬´óÁ¬ÊÐÕþ¸®£¬2013-12-20~2018-12-31£¬2000Íò£¬µÚ1Ãû
´ú±íÎÄÕÂ[1]Hu M£¬Xu L£¬Yin L£¬Qi Y£¬Li H£¬Xu Y£¬Han X£¬Peng J£¬Wan X*.Cytotoxicity of dioscin in human gastric carcinoma cells through death receptor and mitochondrial pathways. J Appl Toxicol£¬2013£¬33(8):712-722. IF(2013£©=3.174. ͨѶ×÷Õß
[2]Wu X£¬Yang N£¬Zhou WH£¬Xu J£¬Chen JJ£¬Zheng FM£¬Long ZJ£¬Yue CF£¬Ai KX£¬Liu LL£¬Wan XY*£¬Liu Q. (2014) Up-regulation of P21 inhibits TRAIL-mediated extrinsic apoptosis, contributing resistance to SAHA in acute myeloid leukemia cells. Cell Physiol Biochem£¬2014£¬34(2):506-518. IF(2014£©=3.55. ͨѶ×÷Õß
[3]Wu X£¬Li S£¬Zhang J£¬Zhang Y£¬Han L£¬Deng Q£¬Wan X*. Meta-analysis of high doses of ambroxol treatment for acute lung injury/acute respiratory distress syndrome based on randomized controlled trials. J Clin Pharmacol£¬2014£¬54(11):1199-1206. IF(2014£©=2.472. ͨѶ×÷Õß
[4]Hou ZJ£¬Luo X£¬Zhang W£¬Peng F£¬Cui B£¬Wu SJ£¬Zheng FM£¬Xu J£¬Xu LZ£¬Long ZJ£¬Wang XT£¬Li GH£¬Wan XY*£¬Yang YL£¬Liu Q. Flubendazole, FDA-approved anthelmintic, targets breast cancer stem-like cells. Oncotarget£¬2015£¬6(8):6326-6340. IF(2015£©=5.008. ͨѶ×÷Õß
[5]ÄÑÖÎÐÔ¸ÐȾÐÔÐÝ¿Ë»¼ÕßÂöѹÓëÔ¤ºóµÄ¹Øϵ³õ̽. ÖлªÄÚ¿ÆÔÓÖ¾£¬2014£¬53(2):121-126. ͨѶ×÷Õß
[6]¶Ô¼±ÐÔºôÎü¾½ÆÈ×ÛºÏÕ÷°ØÁÖ±ê×¼ÖÐÓйØУÕýÑõºÏÖ¸Êý¼ÆË㹫ʽµÄÐÞÕý. ÖлªÄÚ¿ÆÔÓÖ¾£¬2014£¬53(8):677. ͨѶ×÷Õß
[7]½ð»ÆÉ«ÆÏÌÑÇò¾úÄÍÒ©ÐÔÓëÉúÎïĤµÄÏà¹ØÐÔÑо¿. ÖлªÄÚ¿ÆÔÓÖ¾£¬2015£¬54(12):1063-1065. ͨѶ×÷Õß
[8]ÑÏÖØŧ¶¾Ö¢¼°¸ÐȾÐÔÐÝ¿ËÔçÆÚÄ¿±êµ¼ÏòÖÎÁÆÖ®ÏÖ×´¼°Ïà¹ØÎÊÌâ. ÖлªÄÚ¿ÆÔÓÖ¾£¬2016£¬55(6):486-489. ͨѶ×÷Õß
[9]¶ÔÃܶȸÐÖªÐźÅϵͳÔÚMRSA¾úÖê¸ÐȾ¼°ºìùËظÉÔ¤×÷ÓõĹ۲ì. ÖлªÒ½Ñ§ÔÓÖ¾£¬2016£¬96(37):3014-3019. ͨѶ×÷Õß
[10]ÖØ֢ҽѧ¿ÆÄÚÄͼ×ÑõÎ÷ÁÖ½ð»ÆÉ«ÆÏÌÑÇò¾úµÄ·Ö×ÓÁ÷Ðв¡Ñ§µ÷²é. ÖлªÒ½Ñ§ÔÓÖ¾£¬2016£¬96(41):3324-3328. ͨѶ×÷Õß